Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Tulevat kliiniset tutkimukset
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and...Ei vielä rekrytointiaMotoriset taidot | Terve | Johtava toiminta
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCEi vielä rekrytointia
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaEi vielä rekrytointiaNivelreuma | Polven rappeuttava nivelsairausItalia
-
University of Wisconsin, MadisonAlkermes, Inc.Ei vielä rekrytointia
-
Virginia Commonwealth UniversityEi vielä rekrytointia
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at...Ei vielä rekrytointiaKetamiini | fMRI | Masennus – vakava masennus | rTMS | Hoitoresistentti masennus (TRD)Yhdysvallat
-
Weill Medical College of Cornell UniversityBD2 LLCEi vielä rekrytointiafMRI | Kaksisuuntainen mielialahäiriö (BD) | rTMS | Kaksisuuntainen mielialahäiriö 1Yhdysvallat
-
Xentria, Inc.Ei vielä rekrytointia
-
Yale UniversityNational Institute of Mental Health (NIMH)Ei vielä rekrytointia
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRekrytointiFeokromosytooma | Feokromosytooma/paragangliooma | Feokromosytooma, metastaattinen | Pahanlaatuinen feokromosytooma | Feokromosytooma ja paraganglioma (PPGL)Yhdistynyt kuningaskunta
-
Carl Zeiss Meditec-Dublin CoCeRekrytointiEpiretinaalinen kalvo | Verkkokalvon sairaus | Kuivaan ikään liittyvä silmänpohjan rappeuma | Vitreoretinaalinen poikkeavuus | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal...Yhdysvallat
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityRekrytointiCLDN18.2 Positiiviset kiinteät kasvaimetKiina
Clinical Research Jobs
-
Czechia - Brno
-
Belgium - Leuven
-
United Kingdom - Tranent
-
Romania - Bucharest
-
United StatesCanada - Québec - Quebec
-
United Kingdom - Guildford
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China